Delivery Order SPE2DB24D3013-SPE2DB25FFMCH
- Not listed
- The Defense Logistics Agency awarded a $13,125.18 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This firm fixed-price contract, which is a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of April 25, 2025. The award was made through open competition...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $5,085.29 by the Defense Logistics Agency on August 13, 2025, for the supply of Zepbound 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded contract represents a child order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The delivery order...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a $64,579.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with an ultimate completion date of September 18, 2025. This non-competitive delivery order represents a single-line pharmaceutical procurement issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a $4.5K delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injectors, with a completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injectors, valued at $10,709.65 with a firm fixed price structure. The order is scheduled for completion by July 24, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-set-aside competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $13,647.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on May 27, 2025, with a completion date of May 28, 2025. This competitive award, placed under a firm fixed-price contract, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $32,161.80 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This is a firm fixed-price contract with a completion deadline of September 12, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,233.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFMCHDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,988.33 on June 2, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens with an ultimate completion date of June 3, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order supports the Defense Health Agency and military healthcare systems by supplying Zepbound, a GLP-1 receptor agonist medication indicated for weight management. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, maintains an extensive portfolio of delivery orders with DLA covering diverse pharmaceutical products ranging from specialty medications to vaccines and medical supplies. The award demonstrates the company's continued capability to fulfill federal medical supply requirements through competitive procurement processes and its established position as a primary vendor for military healthcare pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 6/2/25 |